Dynamic Expands to Loudoun County, Virginia — Meeting Customer Demand for Secure, Sustainable ITAD and Data Center Services in “Data Center Alley” 
Prompt Infrastructure as the New Battleground for AI Assistants 
Building Real Software Supply Chain Resilience in a Time of Rising Pressure Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
Kura Oncology to Report Second Quarter 2023 Financial Results
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
Kura Oncology to Report Second Quarter 2023 Financial Results
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces…
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces…
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response…
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response…
PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the…
PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the…
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology…
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology…
Tilray Renews Distribution Agreement With Great North Distributors for Cannabis Sales Across Canada With Newly Expanded Brand Portfolio
Tilray Continues to Lead Cannabis Market Share Across Canada LEAMINGTON, Ontario, July 27, 2023 (GLOBE…
Tilray Renews Distribution Agreement With Great North Distributors for Cannabis Sales Across Canada With Newly Expanded Brand Portfolio
Tilray Continues to Lead Cannabis Market Share Across Canada LEAMINGTON, Ontario, July 27, 2023 (GLOBE…
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is…
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is…
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00…
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00…